Baxter International Inc vs Micron Technology, Inc. — how do they compare? Baxter International Inc trades at $26.75 (market cap $14.27B), while Micron Technology, Inc. trades at $924.42 (market cap $980.90B). The key difference: Micron Technology, Inc. is far larger — about 68.7× Baxter International Inc's market cap, and Baxter International Inc pays the higher dividend (0.14%). Which is the better fit depends on your goals.
| BAX | MU | |
|---|---|---|
Market Cap | $14.27B | $980.90B |
Sector | Health | Technology |
52-Week High | $28.35 | $1.21K |
52-Week Low | $15.80 | $115.79 |
Enterprise Value | $21.79B | $961.25B |
Dividend Yield | 0.14% | 0.06% |
Signals from Pluang's Aura AI — not financial advice
Baxter International Inc. (BAX) trades at $27.78, up 0.83% today, with a bullish technical outlook supported by moving averages. Recent Q2 2026 earnings beat estimates with EPS of $0.56 versus $0.37 expected, and revenue guidance was raised, signaling operational improvement. However, the company posted a net loss of -$957 million in 2025, with negative profit margins and high P/E of 87.85, reflecting valuation concerns amid turnaround efforts.
The stock shows potential from earnings momentum and cost initiatives, but high debt and inconsistent profitability pose risks. Analyst consensus is mixed with a $25.43 price target below current levels, suggesting cautious optimism. Investors should weigh recent beats against structural challenges in the medtech sector.
Micron Technology (MU) trades at $861.00, down 1.89% amid recent volatility despite strong fundamental performance. The stock shows neutral technical signals with key support at $845 and resistance at $886. Fundamentally, MU demonstrates exceptional profitability with 72.57% gross margins and 55.91% net income margins, supported by three consecutive quarterly earnings beats. Revenue growth accelerated to $37.38 billion in 2025 from $25.1 billion in 2024, with projected 2026 revenue of $90.3 billion indicating robust AI-driven demand.
The outlook remains positive with 81% analyst buy ratings and $1,540 consensus price target representing 79% upside. However, cyclical memory market risks and competitive threats from new entrants like SpaceX's Terrafab facility pose challenges. The stock's current valuation at 19.63 P/E appears reasonable given projected earnings growth, making MU attractive for investors comfortable with semiconductor sector volatility.
Trailing returns across standard periods
Latest headlines on both assets
Baxter offers a variety of medical instruments and supplies to caregivers. It enhanced its portfolio of hospital-focused offerings by acquiring Hillrom in late 2021. Legacy Baxter offers tools to help patients with acute and chronic kidney failure. It also sells a variety of injectable therapies for use in care settings, such as IV pumps, and administrative sets.
Read more on BAX →Micron historically focused on designing and manufacturing DRAM for PCs. The firm then expanded into the NAND flash memory market. It increased its DRAM scale with the purchase of Elpida (completed in mid-2013) and Inotera (completed in December 2016). The firm's DRAM and NAND products tailored to PCs, data centers, smartphones, game consoles, automotives, and other computing devices.
Read more on MU →